妊娠期低风险甲状腺微小乳头状癌的自然病程:一项前瞻性主动监测研究
单机构前瞻性主动监测队列纳入260例低风险甲状腺微小乳头状癌女性,其中18例(21次妊娠事件)接受超声纵向分析。妊娠期76.2%(16/21)肿瘤加速或中度增长,产后71.4%(15/21)稳定或消退,肿瘤倍增率妊娠期0.39/年 vs 产后-0.01/年(p=0.006)。仅2例需延迟手术,未见手术范围扩大、T分期进展或复发。
要点
- 妊娠期多数低风险甲状腺微小乳头状癌可出现短暂加速生长,产后多稳定或消退。
- 肿瘤倍增率妊娠期峰值0.39/年,产后降至-0.01/年(p=0.006)。
- 仅2例需延迟手术,未见手术范围扩大、T分期进展或复发。
核心结论
- 妊娠可能短暂加速低风险甲状腺微小乳头状癌生长,但多数妊娠期变化为自限性,产后常见稳定或消退。
- 主动监测对育龄患者仍是安全有效的策略,兼顾肿瘤安全与生育力保护。
- 作者认为需结合延长随访和先进影像技术的验证性研究来进一步验证这些发现并优化临床框架。
研究设计与样本
- 单机构前瞻性主动监测队列,2020年2月至2024年10月纳入260例诊断为低风险甲状腺微小乳头状癌的女性患者。
- 18例女性患者(21次妊娠事件)具备完整系列超声记录,接受肿瘤大小和生长速度变化的纵向分析,并按妊娠前、妊娠期、产后进行时间分层比较。
- 计算肿瘤倍增率以量化各时期肿瘤生长或缩小模式,肿瘤大小增加3 mm或以上定义为显著增大。
主要发现
- 中位随访59.0个月(四分位距38.5,72.0)期间,至末次随访时19.0%(4/21)的甲状腺微小乳头状癌病例观察到肿瘤增大(>3 mm)。
- 妊娠期76.2%(16/21)肿瘤表现为加速生长(肿瘤倍增率>0.5/年)或中度生长(肿瘤倍增率0.1-0.5/年),而产后稳定(肿瘤倍增率-0.1至0.1/年)或消退(肿瘤倍增率<-0.1/年)发生于71.4%(15/21)。
- 肿瘤倍增率在妊娠期达峰值,产后下降(0.39/年 vs -0.01/年,p=0.006)。
- 仅2例患者需要延迟手术,未观察到手术范围扩大、T分期进展或肿瘤复发病例。
关键数值与推荐
- 肿瘤大小增加3 mm或以上定义为显著增大。
- 肿瘤倍增率>0.5/年定义为加速生长,0.1-0.5/年为中度生长,-0.1至0.1/年为稳定,<-0.1/年为消退。
临床怎么用
- 作者认为主动监测对育龄低风险甲状腺微小乳头状癌患者仍是安全有效的策略,可平衡肿瘤安全与生育力保护。
- 作者认为需结合延长随访和先进影像技术的验证性研究来进一步验证这些发现并优化临床框架。
局限性
- 作者认为需结合延长随访和先进影像技术的验证性研究来进一步验证这些发现并优化临床框架。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: Active surveillance (AS) has emerged as an established management strategy for patients with low-risk papillary thyroid microcarcinoma (PTMC). However, prior studies have suggested accelerated tumor growth during pregnancy, which raises concerns about the suitability of AS for reproductive-age patients. This study evaluates the longitudinal impact of pregnancy on tumor dynamics and validates the safety of AS management in this population. Methods: From February 2020 to October 2024, a single-institution prospective AS cohort enrolled 260 female patients diagnosed with low-risk PTMC. Eighteen female patients (21 pregnancy events) with complete series of ultrasound documentation underwent longitudinal analysis of changes in tumor size and growth velocity, with time-stratified comparisons before pregnancy, during pregnancy, and after delivery. Tumor doubling rate (TDR) was calculated to quantify tumor growth or shrinkage patterns across these periods. An increase in tumor size of 3 mm or more was defined as substantial enlargement. Results: Over a median follow-up of 59.0 (interquartile range 38.5, 72.0) months, tumor enlargement (>3 mm) was observed in 19.0% (4/21) of the PTMC cases by the last follow-up. During pregnancy, 76.2% (16/21) of tumors exhibited accelerated growth (TDR >0.5/year) or moderate growth (TDR 0.1-0.5/year), whereas postpartum stabilization (TDR -0.1 to 0.1/year) or regression (TDR <-0.1/year) occurred in 71.4% (15/21). The TDR peaked during pregnancy and decreased after delivery (0.39/year vs. -0.01/year, p = 0.006). Delayed surgery was required in only two patients and no instances of expanded surgical scope, T-stage progression, or tumor recurrence were observed. Conclusion: While pregnancy may transiently accelerate tumor growth in low-risk PTMC, most gestational changes are self-limited, with stabilization or regression commonly observed postpartum. AS remains a safe and effective strategy for reproductive-age patients, balancing oncologic safety with fertility preservation. Confirmatory studies incorporating extended follow-up and advanced imaging modalities are essential to further validate these findings and optimize clinical frameworks.
引用
- Liu W, Dong Z, Cao W, et al. The Natural Course of Low-Risk Papillary Thyroid Microcarcinoma During Pregnancy: A Prospective Active Surveillance Study. Thyroid. 2025. PMID: 40402832. doi:10.1089/thy.2024.0702
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。